- Home
- FUSE vs MRSN Comparison
FUSE vs MRSN Comparison
Compare FUSE & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSE
- MRSN
- Stock Information
- Founded
- FUSE 2013
- MRSN 2001
- Country
- FUSE United States
- MRSN United States
- Employees
- FUSE N/A
- MRSN N/A
- Industry
- FUSE EDP Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FUSE Technology
- MRSN Health Care
- Exchange
- FUSE Nasdaq
- MRSN Nasdaq
- Market Cap
- FUSE 48.5M
- MRSN 47.1M
- IPO Year
- FUSE N/A
- MRSN 2017
- Fundamental
- Price
- FUSE $1.82
- MRSN $27.87
- Analyst Decision
- FUSE
- MRSN Buy
- Analyst Count
- FUSE 0
- MRSN 5
- Target Price
- FUSE N/A
- MRSN $30.38
- AVG Volume (30 Days)
- FUSE 433.1K
- MRSN 211.4K
- Earning Date
- FUSE 01-01-0001
- MRSN 11-14-2025
- Dividend Yield
- FUSE N/A
- MRSN N/A
- EPS Growth
- FUSE N/A
- MRSN N/A
- EPS
- FUSE N/A
- MRSN N/A
- Revenue
- FUSE $8,847,000.00
- MRSN $33,180,000.00
- Revenue This Year
- FUSE N/A
- MRSN N/A
- Revenue Next Year
- FUSE N/A
- MRSN N/A
- P/E Ratio
- FUSE N/A
- MRSN N/A
- Revenue Growth
- FUSE 28.65
- MRSN N/A
- 52 Week Low
- FUSE $1.65
- MRSN $5.21
- 52 Week High
- FUSE $4.25
- MRSN $70.73
- Technical
- Relative Strength Index (RSI)
- FUSE N/A
- MRSN 89.87
- Support Level
- FUSE N/A
- MRSN $7.59
- Resistance Level
- FUSE N/A
- MRSN $28.07
- Average True Range (ATR)
- FUSE 0.00
- MRSN 0.69
- MACD
- FUSE 0.00
- MRSN 1.80
- Stochastic Oscillator
- FUSE 0.00
- MRSN 99.51
About FUSE Fusemachines Inc. Common stock
Fusemachines Inc is a provider of enterprise AI products and solutions. The company provides good quality AI education in underserved communities and helping organizations achieve their full potential with AI. The products of the company include AI Studio, Answer Gen, GenAI Engines, and others.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.